{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:35:36Z","timestamp":1794922536153,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100032626","name":"Unitaid","doi-asserted-by":"publisher","award":["2020-39-GLAD"],"award-info":[{"award-number":["2020-39-GLAD"]}],"id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI149665"],"award-info":[{"award-number":["AI149665"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI179309"],"award-info":[{"award-number":["AI179309"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xphs.2025.103927","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:50:13Z","timestamp":1753458613000},"page":"103927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of three anti-HIV drugs tenofovir, lamivudine, and dolutegravir in plasma"],"prefix":"10.1016","volume":"114","author":[{"given":"Luqi","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2383-5057","authenticated-orcid":false,"given":"Shreshtha","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-2686","authenticated-orcid":false,"given":"Masa","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1903-9202","authenticated-orcid":false,"given":"Rachele Delle","family":"Fratte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-3100","authenticated-orcid":false,"given":"Zachary R","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney JY","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.103927_bib0001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/CEOR.S439725","article-title":"The cost-effectiveness of dolutegravir in combination with tenofovir and lamivudine for HIV therapy: a systematic review","volume":"16","author":"Aprilianti","year":"2024","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.xphs.2025.103927_bib0002","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cmdc.202000695","volume":"16","author":"Yoshida","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.xphs.2025.103927_bib0003","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s40265-020-01419-4","article-title":"Lamivudine\/Tenofovir disoproxil fumarate is an appropriate PrEP regimen","volume":"80","author":"Mujugira","year":"2020","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.xphs.2025.103927_bib0004","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"10.1016\/j.xphs.2025.103927_bib0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1208\/s12249-011-9735-6","article-title":"Sensitive and rapid HPLC quantification of Tenofovir from hyaluronic acid-based nanomedicine","volume":"13","author":"Agrahari","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2025.103927_bib0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jchromb.2013.11.054","article-title":"A sensitive HPLC\u2013MS\/MS method for the determination of dolutegravir in human plasma","volume":"945\u2013946","author":"Bennetto-Hood","year":"2014","journal-title":"J Chromatogr B"},{"issue":"3","key":"10.1016\/j.xphs.2025.103927_bib0007","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/17518253.2022.2129463","article-title":"Green HPLC quantification method of lamivudine, zidovudine and nevirapine with identification of related substances in tablets","volume":"15","author":"Vieira-Sella\u00ef","year":"2022","journal-title":"Green Chem Lett Rev"},{"key":"10.1016\/j.xphs.2025.103927_bib0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.9734\/bpi\/napr\/v2\/18487D","article-title":"The development and validation of RP-HPLC method for lamivudine, dolutegravir, and tenfovir in human plasma","volume":"2","author":"Sakinala","year":"2023","journal-title":"Novel Aspects Pharmaceut Res"},{"key":"10.1016\/j.xphs.2025.103927_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115932","article-title":"Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring","volume":"240","author":"West","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2025.103927_bib0010","article-title":"Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form","volume":"1","author":"Nagasarapu","year":"2015","journal-title":"Futur J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.103927_bib0011","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.03.002","article-title":"Intestinal behavior of the ester prodrug tenofovir DF in humans","volume":"485","author":"Geboers","year":"2015","journal-title":"Int J Pharm"},{"issue":"4\u20135","key":"10.1016\/j.xphs.2025.103927_bib0012","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejps.2012.12.025","article-title":"Lamivudine permeability study: a comparison between PAMPA, ex vivo and in situ single-pass intestinal perfusion (SPIP) in rat jejunum","volume":"48","author":"Reis","year":"2013","journal-title":"Euro J Pharmaceut Sci"},{"key":"10.1016\/j.xphs.2025.103927_bib0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1208\/s12249-021-01995-y","article-title":"Enhanced solubility and bioavailability of Dolutegravir by solid dispersion method: In vitro and In vivo evaluation\u2014a potential approach for HIV therapy","volume":"22","author":"Chaudhary","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.xphs.2025.103927_bib0014","first-page":"P90","article-title":"Simultaneous determination of dolutegravir and lamivudine in human plasma by LC-MS\/MS: pharmaceutical sciences-pharmaceutical analysis for novel drug formulation","volume":"11","author":"Bhadrua","year":"2021","journal-title":"Int J Life Sci Pharma Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.103927_bib0015","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.25258\/ijpqa.14.4.58","article-title":"Development and validation of UPLC-MS\/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs Dolutegravir, Lamivudine, and Tenofovir in Human plasma","volume":"14","author":"Vyshali","year":"2023","journal-title":"Int J Pharmaceut Qual Assur"},{"key":"10.1016\/j.xphs.2025.103927_bib0016","series-title":"Guidance for Industry, Bioanalytical Method Validation","year":"2001"},{"issue":"14","key":"10.1016\/j.xphs.2025.103927_bib0017","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/QAD.0000000000003706","article-title":"A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable","volume":"37","author":"Perazzolo","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2025.103927_bib0018","doi-asserted-by":"crossref","first-page":"2087\u20142094","DOI":"10.1002\/rcm.3056","volume":"21","author":"Bennetto-Hood","year":"2007","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.xphs.2025.103927_bib0019","doi-asserted-by":"crossref","first-page":"132\u2014143","DOI":"10.1016\/j.jchromb.2005.04.003","volume":"821","author":"Bezy","year":"2005","journal-title":"J Chromatogr B"},{"issue":"5","key":"10.1016\/j.xphs.2025.103927_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/chromsci\/47.5.365","article-title":"Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors","volume":"47","author":"Kuklenyik","year":"2009","journal-title":"J Chromatogr Sci"},{"issue":"9","key":"10.1016\/j.xphs.2025.103927_bib0021","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4155\/bio.12.76","article-title":"Universal LC-MS method for minimized carryover in a discovery bioanalytical setting","volume":"4","author":"Williams","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.xphs.2025.103927_bib0022","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpba.2018.04.035","article-title":"Development and validation of an LC-MS\/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid","volume":"156","author":"Ocque","year":"2018","journal-title":"J Pharm Biomed Anal"},{"issue":"31","key":"10.1016\/j.xphs.2025.103927_bib0023","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1016\/j.jchromb.2010.10.012","article-title":"Investigation of endogenous blood plasma phospholipids, cholesterol and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography\/mass spectrometry","volume":"878","author":"Ismaiel","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.103927_bib0024","first-page":"73","article-title":"Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form","volume":"1","author":"Mallikarjuna Rao","year":"2015","journal-title":"Futur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2025.103927_bib0025","first-page":"2022","article-title":"The validation of a simple, robust, stability-indicating RP-HPLC method for the simultaneous detection of lamivudine, tenofovir disoproxil fumarate, and dolutegravir sodium in bulk material and pharmaceutical formulations","volume":"3510277","author":"Omoteso","year":"2022","journal-title":"Int J Anal Chem"},{"issue":"6","key":"10.1016\/j.xphs.2025.103927_bib0026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/14690667211058564","article-title":"Development and validation of ultra performance liquid chromatography-tandem mass spectrometry method for the simultaneous estimation of dolutegravir, lamivudine and tenofovir in bulk and tablet dosage form","volume":"27","author":"Veerareddy","year":"2021","journal-title":"Euro J Mass Spectrom"},{"issue":"1","key":"10.1016\/j.xphs.2025.103927_bib0027","doi-asserted-by":"crossref","first-page":"5","DOI":"10.47583\/ijpsrr.2023.v83i01.002","article-title":"Development and validation of LC-MS\/MS method for simultaneous estimation of emtricitabine, tenofovir alafenamide and dolutegravir in human plasma","volume":"83","author":"Rajendra","year":"2023","journal-title":"Int J Pharm Sci Rev Res"},{"key":"10.1016\/j.xphs.2025.103927_bib0028","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpba.2018.04.035","article-title":"Development and validation of an LC-MS\/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid","volume":"156","author":"Ocque","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2025.103927_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2020.113611","article-title":"An LC-MS\/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer","volume":"593","author":"Xiao","year":"2020","journal-title":"Anal Biochem"},{"key":"10.1016\/j.xphs.2025.103927_bib0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ph14010012","article-title":"Validation of a UHPLC-MS\/MS method to quantify twelve antiretroviral drugs within peripheral blood mononuclear cells from people living with HIV","volume":"14","author":"De Nicol\u00f2","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xphs.2025.103927_bib0031","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2018.12.008","article-title":"Development and validation of an UPLC-MS\/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma","volume":"1105","author":"Bollen","year":"2019","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.xphs.2025.103927_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115932","article-title":"Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring","volume":"240","author":"West","year":"2024","journal-title":"J Pharm Biomed Anal"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492500379X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492500379X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:52:58Z","timestamp":1772787178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492500379X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S002235492500379X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103927","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of three anti-HIV drugs tenofovir, lamivudine, and dolutegravir in plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"103927"}}